Wire · opportunities
FDA clears C2N Diagnostics' early Alzheimer's assessment test
◆ Sectors
◆ Geography
◆ Source
◆ Verified
Fusion42 · 21 August 2026 · Fusion42 review
C2N Diagnostics received FDA clearance for its PrecivityAD2 blood test, the first Alzheimer's assessment approved for patients as young as 40, aiding earlier detection of amyloid pathology linked to Alzheimer's disease. The test supports clinical evaluation but is not a standalone diagnostic. This positions C2N competitively alongside Roche in a rapidly growing market anticipated to reach $33bn by 2033.
This Wire brief sits within Fusion42's coverage of Diagnostics, and 4 sources have reported it between 20 Aug 2026 and 21 Aug 2026.
◆ ◆ The Wire takeaway
You can now offer earlier Alzheimer’s assessment starting at age 40 in the US, expanding your potential patient base. This shifts the competitive balance and opens new pathways against Roche’s tests and for precision diagnostics.
◆ Coverage
4 sources · first reported 20 Aug 2026 · latest 21 Aug 2026
◆ Related on Wire
◆ Topics